GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Drug: GSK2982772 solutionDrug: GSK2982772 capsuleDrug: Placebo solutionDrug: Placebo capsule
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 79
- Registration Number
- NCT02302404
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Procedure: SpirometryOther: ACOS clinical questionnaire
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1215
- Registration Number
- NCT02302417
- Locations
- 🇺🇦
GSK Investigational Site, Kyiv, Ukraine
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Placebo inhalation powders via ELLIPTA inhalerDrug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1526
- Registration Number
- NCT02301975
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2018-08-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 184
- Registration Number
- NCT02299375
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Biological: RSV F subunit 45 μg MF59 adjuvantBiological: RSV F subunit 90 μg No adjuvantBiological: RSV F subunit 45 μg Aluminum hydroxide adjuvantBiological: RSV F subunit 45 μg No adjuvantBiological: RSV F subunit 135 μg Aluminum hydroxide adjuvantDrug: PlaceboBiological: RSV F subunit 90 μg Aluminum hydroxide adjuvantBiological: RSV F subunit 135 μg MF59 adjuvantBiological: RSV F subunit 90 μg MF59 adjuvantBiological: RSV F subunit 135 μg No adjuvant
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 288
- Registration Number
- NCT02298179
- Locations
- 🇧🇪
GSK Investigational Site, Ghent, Belgium
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT02294734
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 106
- Registration Number
- NCT02294682
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT02293161
- Locations
- 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom
Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Anaemia
- Interventions
- Drug: GSK1278863 500 mgDrug: GSK1278863 75 mgDrug: Placebo matching GSK1278863Drug: Placebo matching Moxifloxacin
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 61
- Registration Number
- NCT02293148
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Cross-sectional Study for Identification and Description of Severe Asthma Patients
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: Short Acting Beta Agonist (SABA)
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 767
- Registration Number
- NCT02293265
- Locations
- 🇬🇧
GSK Investigational Site, Trowbridge, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath